These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 18209648)

  • 21. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
    Goñi FJ;
    Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%.
    Chan K; Testa M; McCluskey P
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):372-6. PubMed ID: 17803436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.
    Mungan NK; Wilson TW; Nischal KK; Koren G; Levin AV
    J AAPOS; 2003 Feb; 7(1):69-70. PubMed ID: 12690374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy.
    Lee JS; Kim CY
    Expert Rev Clin Pharmacol; 2022 Aug; 15(8):911-919. PubMed ID: 35951740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anterior uveitis and topical brimonidine: a case report].
    Velasque L; Ducousso F; Pernod L; Vignal R; Deral V
    J Fr Ophtalmol; 2004 Dec; 27(10):1150-2. PubMed ID: 15687926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allergic contact dermatitis caused by topical eye drops.
    Spaeth GL
    Am J Ophthalmol; 2006 Oct; 142(4):706. PubMed ID: 17011880
    [No Abstract]   [Full Text] [Related]  

  • 28. Preclinical safety profile of brimonidine.
    Angelov OV; Wiese AG; Tang-Liu DD; Acheampong AA; Ismail IM; Brar BS
    Eur J Ophthalmol; 1996; 6(1):21-5. PubMed ID: 8744846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is brimonidine ophthalmic a safe therapy for infants?
    Daubert GP
    J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cicatricial ectropion: a complication of topical 5-fluorouracil.
    Nikkhah D; Abood A; Watt D
    J Plast Reconstr Aesthet Surg; 2012 Jan; 65(1):e9-10. PubMed ID: 21872544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of glaucoma with brimonidine (Alphagan 0.2%)].
    Detry-Morel M; Dutrieux C
    J Fr Ophtalmol; 2000 Oct; 23(8):763-8. PubMed ID: 11033496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
    Greenfield DS; Liebmann JM; Ritch R
    J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy.
    Gordon RN; Liebmann JM; Greenfield DS; Lama P; Ritch R
    Eye (Lond); 1998; 12 ( Pt 4)():697-700. PubMed ID: 9850267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial.
    Wilhelm B; Lüdtke H; Wilhelm H;
    Graefes Arch Clin Exp Ophthalmol; 2006 May; 244(5):551-8. PubMed ID: 16151785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitreous concentration of topically applied brimonidine-purite 0.15%.
    Kent AR; King L; Bartholomew LR
    J Ocul Pharmacol Ther; 2006 Aug; 22(4):242-6. PubMed ID: 16910864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alphagan allergy may increase the propensity for multiple eye-drop allergy.
    Osborne SA; Montgomery DM; Morris D; McKay IC
    Eye (Lond); 2005 Feb; 19(2):129-37. PubMed ID: 15254495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iopidine allergy causing lower eyelid ectropion progressing to cicatricial entropion.
    Britt MT; Burnstine MA
    Br J Ophthalmol; 1999 Aug; 83(8):992-3. PubMed ID: 10636681
    [No Abstract]   [Full Text] [Related]  

  • 39. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma.
    Korsch E; Grote A; Seybold M; Soditt V
    Eur J Pediatr; 1999 Aug; 158(8):685. PubMed ID: 10445353
    [No Abstract]   [Full Text] [Related]  

  • 40. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate.
    Becker HI; Walton RC; Diamant JI; Zegans ME
    Arch Ophthalmol; 2004 Jul; 122(7):1063-6. PubMed ID: 15249377
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.